↓ Skip to main content

Dove Medical Press

Article Metrics

Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections

Overview of attention for article published in Drug Design, Development and Therapy, June 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (62nd percentile)
  • High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

twitter
4 tweeters

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
38 Mendeley
Title
Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections
Published in
Drug Design, Development and Therapy, June 2015
DOI 10.2147/dddt.s61436
Pubmed ID
Authors

Marion Skalweit

Abstract

Drug-resistant pathogens have gained a foothold especially in the most vulnerable patient populations, hospitalized and immunocompromised individuals. Furthermore, extended-spectrum β-lactamase and carbapenemase-producing organisms are finding their way even into the community, with patients presenting to the hospital with established colonization and infection with resistant Enterobacteriaceae in particular. Recently, a novel antipseudomonal cephalosporin in combination with an established Class A β-lactamase inhibitor, ceftolozane/tazobactam has been approved by the FDA for use in the treatment of complicated urinary tract infections and complicated intra-abdominal infections. Ceftolozane is a uniquely potent antipseudomonal cephalosporin because of its high affinity for the penicillin-binding proteins of Pseudomonas aeruginosa, its low affinity for the intrinsic Class C β-lactamases of P. aeruginosa, its ability to enter P. aeruginosa through the outer membrane without the utilization of OprD protein, and the fact that it is not a substrate of the often upregulated MexAB/OprM efflux system of P. aeruginosa. The biological chemistry, pharmacokinetics/pharmacodynamics, microbiologic spectrum, and clinical trials that led to the approval of ceftolozane is reviewed. A discussion regarding its potential role in the treatment of complicated intra-abdominal infections and other infectious disease syndromes associated with drug-resistant pathogens follows.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 38 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 16%
Other 6 16%
Student > Master 5 13%
Student > Bachelor 4 11%
Student > Doctoral Student 4 11%
Other 7 18%
Unknown 6 16%
Readers by discipline Count As %
Medicine and Dentistry 20 53%
Biochemistry, Genetics and Molecular Biology 4 11%
Pharmacology, Toxicology and Pharmaceutical Science 3 8%
Agricultural and Biological Sciences 2 5%
Chemistry 1 3%
Other 0 0%
Unknown 8 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 February 2016.
All research outputs
#2,822,036
of 7,200,541 outputs
Outputs from Drug Design, Development and Therapy
#181
of 941 outputs
Outputs of similar age
#78,652
of 216,887 outputs
Outputs of similar age from Drug Design, Development and Therapy
#18
of 122 outputs
Altmetric has tracked 7,200,541 research outputs across all sources so far. This one has received more attention than most of these and is in the 60th percentile.
So far Altmetric has tracked 941 research outputs from this source. They receive a mean Attention Score of 3.1. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 216,887 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.
We're also able to compare this research output to 122 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.